The outpatient prescription volume of antidiabetic dipeptidyl peptidase 4 (DPP-4) inhibitors exceeded over 600 billion won for the first time in the history. The market is steadfastly growing with about 6 percent surge from last year. The experts hint the oral antidiabetic drug market was the key to the growth.

The sodium-glucose cotransporter-2 (SGLT2) inhibitor market is constantly and exponentially expanding with Forxiga and Jardiance. The last year’s prescription volume grew 29 percent from the year before and marked 121.4 billion won.

◆DPP-4 inhibitor market volume expands by 6 percent and hits 602.4 billion won

According to a pharmaceutical market research fir